EP4167976A4 - Cannabinoïdes encapsulés dans des nanoparticules et leurs procédés de fabrication et d'utilisation - Google Patents

Cannabinoïdes encapsulés dans des nanoparticules et leurs procédés de fabrication et d'utilisation Download PDF

Info

Publication number
EP4167976A4
EP4167976A4 EP21826754.0A EP21826754A EP4167976A4 EP 4167976 A4 EP4167976 A4 EP 4167976A4 EP 21826754 A EP21826754 A EP 21826754A EP 4167976 A4 EP4167976 A4 EP 4167976A4
Authority
EP
European Patent Office
Prior art keywords
nanoparticle
production
methods
encapsulated cannabinoids
cannabinoids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP21826754.0A
Other languages
German (de)
English (en)
Other versions
EP4167976A1 (fr
Inventor
Naomie LUCAS
Eric SEIDEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nurevelation LLC
Original Assignee
Nurevelation LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nurevelation LLC filed Critical Nurevelation LLC
Publication of EP4167976A1 publication Critical patent/EP4167976A1/fr
Publication of EP4167976A4 publication Critical patent/EP4167976A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Carbon And Carbon Compounds (AREA)
EP21826754.0A 2020-06-19 2021-06-18 Cannabinoïdes encapsulés dans des nanoparticules et leurs procédés de fabrication et d'utilisation Withdrawn EP4167976A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063041544P 2020-06-19 2020-06-19
PCT/US2021/037989 WO2021257935A1 (fr) 2020-06-19 2021-06-18 Cannabinoïdes encapsulés dans des nanoparticules et leurs procédés de fabrication et d'utilisation

Publications (2)

Publication Number Publication Date
EP4167976A1 EP4167976A1 (fr) 2023-04-26
EP4167976A4 true EP4167976A4 (fr) 2024-08-07

Family

ID=79171603

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21826754.0A Withdrawn EP4167976A4 (fr) 2020-06-19 2021-06-18 Cannabinoïdes encapsulés dans des nanoparticules et leurs procédés de fabrication et d'utilisation

Country Status (5)

Country Link
EP (1) EP4167976A4 (fr)
AU (1) AU2021293266A1 (fr)
BR (1) BR112022025912A2 (fr)
CA (1) CA3183022A1 (fr)
WO (1) WO2021257935A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220062190A1 (en) * 2020-08-28 2022-03-03 NuRevelation, LLC Therapeutic Agent and Nutraceutical Compositions And Methods for Making and Using Same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019159174A1 (fr) * 2018-02-16 2019-08-22 Icdpharma Ltd. Administration, dans le côlon, de cannabinoïdes dans des compositions de solution solide
US20200054702A1 (en) * 2017-05-01 2020-02-20 Michael Heller Methodology and Formulation for Creating a Powder of an Encapsulated Cannabis-Based Component Embedded in a Polymer Matrix
US20200138072A1 (en) * 2018-11-01 2020-05-07 Molecular Infusions, Llc Polymer-based oral cannabinoid and/or terpene formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2985332C (fr) * 2015-05-18 2023-01-03 5071, Inc. Compositions de cannabis homogenes et methodes de preparation
EP3655009B1 (fr) * 2017-07-20 2023-10-11 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Compositions de nanoparticules
SI25647A2 (sl) * 2018-05-09 2019-11-29 Organic Tech Dwc Llc Vodne raztopine kanabinoidov

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200054702A1 (en) * 2017-05-01 2020-02-20 Michael Heller Methodology and Formulation for Creating a Powder of an Encapsulated Cannabis-Based Component Embedded in a Polymer Matrix
WO2019159174A1 (fr) * 2018-02-16 2019-08-22 Icdpharma Ltd. Administration, dans le côlon, de cannabinoïdes dans des compositions de solution solide
US20200138072A1 (en) * 2018-11-01 2020-05-07 Molecular Infusions, Llc Polymer-based oral cannabinoid and/or terpene formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021257935A1 *

Also Published As

Publication number Publication date
CA3183022A1 (fr) 2021-12-23
AU2021293266A1 (en) 2023-02-02
WO2021257935A1 (fr) 2021-12-23
EP4167976A1 (fr) 2023-04-26
BR112022025912A2 (pt) 2023-05-02

Similar Documents

Publication Publication Date Title
EP3652575C0 (fr) Ruban de fibres optiques et son procédé de production
EP4126531A4 (fr) Géogrille multiaxiale intégrée et procédés de fabrication et d'utilisation d'une telle géogrille
EP3768408A4 (fr) Nanocomposites à base d'halloysite et procédés de production et d'utilisation associés
EP4419569A4 (fr) Polymères de saccharide fonctionnalisés par un acide aminocarboxylique et leurs procédés de production et d'utilisation
EP4298259A4 (fr) Alliages d'aluminium et leurs procédés de fabrication et d'utilisation
EP4426314A4 (fr) Inhibiteurs de pi3k-alpha et leurs méthodes de préparation et d'utilisation
EP4125369A4 (fr) Produits de protéine de pongamia, et leurs procédés de production et d'utilisation
EP4359420A4 (fr) 25-hydroxy-cholest-5-en-3-sulfate choline, leurs procédés de préparation, et leurs utilisations
EP4103700A4 (fr) Compositions d'hydrogel contenant un cocktail de bactériophages et leurs procédés de production et d'utilisation
EP4330362C0 (fr) Utilisation et procédé pour produire des mono-rhamnolipides
EP4330418C0 (fr) Utilisation et procédé de production de mono-rhamnolipides
EP3884034A4 (fr) Procédés et compositions pour produire des cannabinoïdes
EP4360624A4 (fr) Nanoparticules lipidiques et procédé pour leur préparation
EP4252540A4 (fr) Ingrédient protéiné de forme tissulaire et procédé de production associé
EP4422700A4 (fr) Structures d'hydrogel et leurs procédés de fabrication et d'utilisation
EP4109638A4 (fr) Élément électrochimique et son procédé de fabrication
EP4037491A4 (fr) Compositions de pongamia comestibles et leurs procédés de préparation et d'utilisation
EP3829533C0 (fr) Composition d'écran solaire, utilisation de la composition d'écran solaire et procédé de fabrication de la composition d'écran solaire
EP4429702A4 (fr) Compositions comprenant des composés de lipides aminés et leurs procédés de fabrication et d'utilisation
EP4171543A4 (fr) Nanoparticules et leurs procédés de fabrication
EP4382661A4 (fr) Cuir synthétique, et procédé de fabrication de celui-ci
EP4284408A4 (fr) Procédés de préparation de sécrétomes et leurs utilisations
EP4241796A4 (fr) Matériau biocompatible et son procédé de production
EP4269691A4 (fr) Article façonné moulé en pâte fibreuse et son procédé de fabrication
EP4155264A4 (fr) Composition, et procédé de fabrication de celle-ci

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031010000

Ipc: A61K0031050000

A4 Supplementary search report drawn up and despatched

Effective date: 20240708

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/51 20060101ALI20240702BHEP

Ipc: A61K 9/14 20060101ALI20240702BHEP

Ipc: A61K 31/353 20060101ALI20240702BHEP

Ipc: A61K 31/352 20060101ALI20240702BHEP

Ipc: A61K 31/05 20060101AFI20240702BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20250103